



# CUPID LIMITED

Manufacturers and Suppliers of Male & Female Condoms

Date: - 05/11/2020

To,

Department of Corporate Services,

BSE LIMITED,

Phiroze Jeejeebhoy Towers,

Dalal Street,

Mumbai – 400 001

SCRIP CODE: 530843

The National Stock Exchange of India Ltd.

Exchange Plaza, 5<sup>th</sup> Floor, Bandra-Kurla

Complex, Bandra (East),

Mumbai - 400051

Fax No. – 6641 8125 / 26

SCRIP CODE: CUPID

**Subject:** -Outcome of Board Meeting.

Dear Sir / Madam,

With reference to captioned subject, we attached herewith the detail statement of outcome of Board Meeting pursuant to regulation 30 of Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015.

Kindly take the same on your records and acknowledge the receipt.

By the order of the Board of Directors

For Cupid Limited

Saurabh V. Karmase



Company Secretary and Compliance Officer

ECSIN: EA041701A000083921

CIN No : L25193MH1993PLC070846

Factory & Registered Office:

A-68, M.I.D.C. (Malegaon), Sinnar, Nashik - 422113, Maharashtra, India

Tel: +91 2551 230280 / 230772 / +91 7722009580 Email: info@cupidlimited.com, Website: www.cupidlimited.com



# CUPID LIMITED

Manufacturers and Suppliers of Male & Female Condoms

## OUTCOME OF BOARD MEETING

**November 5<sup>th</sup>, 2020:**

The Board of Directors of the Cupid Limited at its meeting held on November 5<sup>th</sup>, 2020, inter alia, had considered and approved the following matters:-

Commencement time of Board Meeting: - 05.45 P.M.

Conclusion time of Board Meeting: - 08.10 P.M.

1. Quarterly reports submitted to BSE Limited and National Stock Exchange of India Limited for period ended 30<sup>th</sup> September, 2020 were considered and reviewed by the Board.
2. Unaudited Financial Results for quarter ended 30<sup>th</sup> September, 2020 were considered and adopted by the Board.
3. Board of Directors had considered and declared the 1<sup>st</sup> Interim Dividend for the financial year 2020-2021 at the rate of Re. 1/- per equity share of Rs. 10/- each (i.e. 10 %).

The Board had also confirmed 20<sup>th</sup> November, 2020 as record date, the shareholders whose name appeared in the register on the record date are entitled for the dividend.

Further, the payment of dividend shall be made on December 2<sup>nd</sup>, 2020.

4. The Directors Report for year ended 31<sup>st</sup> March, 2020 was considered and approved by the Board.
5. The Notice to Members / Shareholders for 27<sup>th</sup> Annual General Meeting of the company was considered and approved by the Board.
6. Mr. Shailesh Kachalia, Practicing Company Secretary, appointed as Scrutiniser for 27<sup>th</sup> Annual General Meeting of the company.
7. The board has decided and approved manufacturing of Medical Devices including various testing kits / diagnosing kits in a new division as Diagnostic Division and for

*Saunsh*

CIN No : L25193MH1993PLC070846

Factory & Registered Office:

A-68, M.I.D.C. (Malegaon), Sinnar, Nashik - 422113, Maharashtra, India

Tel: +91 2551 230280 / 230772 / +91 7722009580 Email: info@cupidlimited.com, Website: www.cupidlimited.com





# CUPID LIMITED

Manufacturers and Suppliers of Male & Female Condoms

which the company has entered into Service Provider and License Agreement with Invex Health Private Limited.

By the order of the Board of Directors  
For Cupid Limited



**Saurabh V. Karmase**

**Company Secretary and Compliance Officer**

**ECSIN: EA041701A000083921**

Place: - Mumbai

Date: - 05/11/2020

**Enclosures:**

1. Annexure A: Profile of Mr. Shailesh Kachalia
2. Annexure B: Brief details of agreement between Cupid Limited and Invex Health Private Limited

# CS SHAILESH KACHALIA

Contact No.: +91-9892534153

E-Mail: shaileshmay@gmail.com

---

## QUALIFICATIONS. :

1. B.COM. (HONS) MUMBAI UNIVERSITY (1977)
2. LLB MUMBAI UNIVERSITY (1981)
3. FELLOW MEMBER OF THE INSTITUTE OF COMPANY SECRETARIES OF INDIA (1981)
4. SEVEN DAYS COURSE ORGANIZED BY INDIAN MERCHANT CHAMBERS MUMBAI IN ARBITRATION.

## EXPERIENCE AS FULL TIME COMPANY SECRETARY:-

I WORKED AS FULL TIME COMPANY SECRETARY FROM NOVEMBER 1981 TO DECEMBER 1994 WITH FOLLOWING ORGANISATIONS:-

1. 12 MONTHS WITH M/s. WARIOR INVESTMENTS LIMITED (UNLISTED CO.)
2. 18 MONTHS WITH M/S. UNIVERSAL STARCH CHEM ALLIED INDUSTRIES LIMITED (LISTED CO.)
3. 66 MONTHS WITH M/s. MODERN MILLS LIMITED (LISTED CO.)
4. 6 MONTHS WITH BEE ELETRONICS LIMITED (LISTED CO.)
5. 15 MONTHS WITH RELIANCE PETROCHEMICALS LIMITED (LISTED CO.)
6. 15 MONTHS WITH LAN ESEDA GROUP OF COMPANIES (LISTED)
7. 12MONTHS WITH POOJA CAPITAL FINANCE LIMITED (UNLISTED)

## EXPERIENCE AS FULL TIME PRACTICING COMPANY SECRETARY:-

SINCE 1995 I HAVE MY INDEPENDENT PRACTICE AND HOLDING CERTIFICATE OF PRACTICE FROM MORE THAN 15 YEARS.

HAVE PRACTICAL EXPERIENCE OF 35 YEARS IN ADMISTRATION OF THE PROVISIONS OF THE COMPANIES ACT, 1956/2013, SEBI GUIDELINES, STOCK EXCHANGE FORMALITIES, AND COMPANY LAW BOARD MATTERS.

## PERSONAL DETAILS:

DATE OF BIRTH: - 16TH APRIL1956.

ADDRESS: - OM SRI CHS LTD., A WING, FIRST FLOOR, FLAT NO 7. NEAR SHANTI ASHRAM, OFF LINK ROAD, BORIVALI (WEST), MUMBAI 400103.

MEMBERSHIP NO. : - FCS 1391

COP NO. : - 3888

LANGUAGES KNOWN: - ENGLISH, HINDI, MARATHI, GUJRATHI AND MARWARI

## ANNEXURE B

### BRIEF DETAILS OF AGREEMENT BETWEEN CUPID LIMITED ('CUPID') AND INVEX HEALTH PRIVATE LIMITED ('INVEX')

Arrangement for strategic, technical, manufacturing, or marketing tie-up:

SR. NO.	PARTICULARS	DISCLOSURES
i.	Name of the entity(ies) with whom agreement is signed	Invex Health Private Limited
ii.	Area of agreement	Service Provider and Licensing Agreement
iii.	Domestic / International	Domestic
iv.	Share Exchange Ratio	Not Applicable
v.	Scope of Business Operation of Agreement	Invex will Assist in Manufacturing, Marketing, Licensing, etc. of Medical Devices Including Various Testing Kits / Diagnosing Kits.
vi.	Details of consideration paid / received in agreement	INR 1 Crore.
vii.	Significant terms and conditions of agreement	A.Initial term of this agreement is of 7 years which will be automatically renewable for further term of 7 years.  B.The Initial Maximum Investment towards Capital expenditure for the Diagnostics Division to be made by Cupid shall be INR 10 Crore.

		C. In lieu of Rs. INR 1 Crore And services as mentioned in point no. v above, Invex will get right to participate in Profit and /or cash losses for the diagnostic division in the ratio of 50:50.
viii.	Whether the acquisition would fall within related party transactions and whether the promoter/ promoter group/ group companies have any interest in the entity being acquired? If yes, nature of interest and details thereof and whether the same is done at arm's length.	Not Applicable
ix.	Rationale and benefit expected	In India and around the Globe, the diagnostic market is expected to grow at healthy rate in nearby future. To capitalize on this opportunity, Cupid intended to Manufacture the quality diagnostic kits as a rewarding prospect in India supporting self-reliant India and manufacturing base of supply of quality kits to the World.